Long interspersed nucleotide element-1 (LINE-1) methylation in colorectal cancer

Kerachian, Mohammad Amin; Kerachian, Mohammad Amin

doi:10.1016/j.cca.2018.11.018

Cited by 53 publications

(34 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In several types of tumors, including ESCC [28,29], LINE-1 hypomethylation has been found to be associated with a poor prognosis [34][35][36]. Unfortunately, due to the limited number of patients examined, we were unable to determine any correlation between hypomethylation status and patient outcome.…”

Section: Line-1 Methylation Analysis In Cfdnamentioning

confidence: 94%

Detection of LINE-1 hypomethylation in cfDNA of Esophageal Adenocarcinoma Patients

Boldrin

Curtarello

Dallan

et al. 2020

IJMS

View full text Add to dashboard Cite

DNA methylation plays an important role in cancer development. Cancer cells exhibit two types of DNA methylation alteration: site-specific hypermethylation at promoter of oncosuppressor genes and global DNA hypomethylation. This study evaluated the methylation patterns of long interspersed nuclear element (LINE-1) sequences which, due to their relative abundance in the genome, are considered a good surrogate indicator of global DNA methylation. LINE-1 methylation status was investigated in the cell-free DNA (cfDNA) of 21 patients, 19 with esophageal adenocarcinoma (EADC) and 2 with Barrett’s esophagus (BE). The two BE patients and one EADC patient were also analyzed longitudinally. Methylation status was analyzed using restriction enzymes and DNA amplification. This methodology was chosen to avoid bisulfite conversion, which we considered inadequate for cfDNA analysis. Indeed, cfDNA is characterized by poor quality and low concentration, and bisulfite conversion might worsen these conditions. Results showed that hypomethylated LINE-1 sequences are present in EADC cfDNA. Furthermore, longitudinal studies in BE suggested a correlation between methylation status of LINE-1 sequences in cfDNA and progression to EADC. In conclusion, our study indicated the feasibility of our methodological approach to detect hypomethylation events in cfDNA from EADC patients, and suggests LINE-1 methylation analysis as a new possible molecular assay to integrate into patient monitoring.

show abstract

Section: Line-1 Methylation Analysis In Cfdnamentioning

confidence: 94%

Detection of LINE-1 hypomethylation in cfDNA of Esophageal Adenocarcinoma Patients

Boldrin

Curtarello

Dallan

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…This report was observed among Japanese moving to the United States in 1960s, when the number of CRC cases had increased [7]. This cancer is a multifactorial disease, involving genetic, epigenetic and environmental risk factors [8].…”

Section: Introductionmentioning

confidence: 90%

Association of MTHFR C677T Variant Genotype with Serum Folate and Vit B12 in Iranian Patients with Colorectal Cancer or Adenomatous Polyps

Ghorbani

Baharara

Kerachian

2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: The incidence of colorectal cancer (CRC) has increased vigorously during the last decades in Iran and clinical studies suggest that moderate deficiency of methylenetetrahydrofolate reductase (MTHFR) and essential folate dietary intake may reduce the risk of CRC.The aim of this study was to investigate the clinical significance of C677T polymorphism within MTHFR gene and its correlation with the serum folate and Vit B12 in Iranian population suffering from CRC.Methods: Blood samples were taken from 207 Iranian individuals (103 males and 104 females) who were referred for colonoscopy. TaqMan probe assay was performed for C677T MTHFR polymorphism. Besides, sera were fractionated from the blood samples of 43 patients and controls and folate and Vit B12 concentrations were measured by a monobind kit. Finally, the correlation of MTHFR polymorphisms and folate/vitamin-B12 with CRC risk were analyzed.Results: In the current study, the most percentage of the MTHFR polymorphisms in healthy individuals belongs to CC genotype (wild type). In patients with adenoma the percentage of CC and CT genotype were approximately similar, but surprisingly in adenocarcinoma the percentage of CC genotype (wild type) was the highest (approximately 50%), and the percentage of CT and TT genotypes were slightly similar. Our study revealed that there was no significant difference between the amount of folate and Vit B12 in case and control groups (p value >0.05).Conclusions: We concluded that there is an association between pivotal concentration of serum folate/vitamin B12 and CRC, and this association is altered by MTHFR C677T genotype.

show abstract

“…Circulating tumor DNA or ctDNA can be released from CTCs, primary tumors, and secondary tumors into the circulation of cancer patients, and can be bound to complex proteins, cell surfaces, or vesicles [82]. Different kinds of tumor-specific DNA aberrations may be recorded in cfDNA, such as point mutations, loss of heterozygosity (LOH; gene amplifications; presence of viral oncogenic DNA; hypermethylation of tumor suppressor gene promoter areas; and hypomethylation of long, interspersed nucleotide element-1 [83][84][85]. The ctDNA is more fragmented than normal cfDNA [86] and it can exist at sizes less than 1000 bp [42].…”

Section: Cell Free Circulating Tumor Dnamentioning

confidence: 99%

Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma

et al. 2020

View full text Add to dashboard Cite

Owing to the advancement of technology combined with our deeper knowledge of human nature and diseases, we are able to move towards precision medicine, where patients are treated at the individual level in concordance with their genetic profiles. Lately, the integration of nanoparticles in biotechnology and their applications in medicine has allowed us to diagnose and treat disease better and more precisely. As a model disease, we used a grade IV malignant brain tumor (glioblastoma). Significant improvements in diagnosis were achieved with the application of fluorescent nanoparticles for intraoperative magnetic resonance imaging (MRI), allowing for improved tumor cell visibility and increasing the extent of the surgical resection, leading to better patient response. Fluorescent probes can be engineered to be activated through different molecular pathways, which will open the path to individualized glioblastoma diagnosis, monitoring, and treatment. Nanoparticles are also extensively studied as nanovehicles for targeted delivery and more controlled medication release, and some nanomedicines are already in early phases of clinical trials. Moreover, sampling biological fluids will give new insights into glioblastoma pathogenesis due to the presence of extracellular vesicles, circulating tumor cells, and circulating tumor DNA. As current glioblastoma therapy does not provide good quality of life for patients, other approaches such as immunotherapy are explored. To conclude, we reason that development of personalized therapies based on a patient’s genetic signature combined with pharmacogenomics and immunogenomic information will significantly change the outcome of glioblastoma patients.

show abstract

Long interspersed nucleotide element-1 (LINE-1) methylation in colorectal cancer

Cited by 53 publications

References 79 publications

Detection of LINE-1 hypomethylation in cfDNA of Esophageal Adenocarcinoma Patients

Detection of LINE-1 hypomethylation in cfDNA of Esophageal Adenocarcinoma Patients

Association of MTHFR C677T Variant Genotype with Serum Folate and Vit B12 in Iranian Patients with Colorectal Cancer or Adenomatous Polyps

Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma

Contact Info

Product

Resources

About